Press Releases

September 26, 2024 | 3rd Party Submission

CaaMTech Inc. U.S. Patent Application 18/392,759 | Porta Sophia Files Third Party Submission

Patent application: tryptamine derivatives and compositions for use in treating various diseases

View Press Release

September 25, 2024 | 3rd Party Submission

Beckley Psytech Ltd. U.S. Patent Application 18/365,699 | Porta Sophia Files Third Party Submission

Patent application: pharmaceutically acceptable salts of 5-MeO-DMT with X-Ray Powder Diffraction analysis

View Press Release

September 13, 2024 | 3rd Party Submission

Mind Medicine Inc. U.S. Patent Application 18/543,789 | Porta Sophia Files Third Party Submission

Patent application: synthesis of MDMA prodrugs through unscheduled intermediates

View Press Release

September 6, 2024 | 3rd Party Submission

Turtle Bear Holdings LLC U.S. Patent Application 18/498,563 | Porta Sophia Files Third Party Submission

Patent application: combinations of tryptamines and fungal compounds to treat neuroinflammation

View Press Release

September 3, 2024 | 3rd Party Submission

ATAI Life Sciences AG U.S. Patent Application 18/244,078 | Porta Sophia Files Third Party Submission

Patent application: therapeutic use of R-MDMA for stress related disorders

View Press Release

August 29, 2024 | 3rd Party Submission

CaaMTech Inc. U.S. Patent Application 18/260,711 | Porta Sophia Files Third Party Submission

Patent application: protected tryptamines for therapeutic uses including inflammation

View Press Release

August 21, 2024 | 3rd Party Submission

Remy Biosciences, Inc. U.S. Patent Application 17/824,901 | Porta Sophia Files Third Party Submission

Patent application: transdermal delivery of psilocybin and psilocin

View Press Release

August 15, 2024 | 3rd Party Submission

Agnieszka Dorota Sekula U.S. Patent Application 18/500,921 | Porta Sophia Files Third Party Submission

Patent application: virtual reality protocols for psychedelic-assisted therapy

View Press Release

August 13, 2024 | 3rd Party Submission

New York University U.S. Patent Application 18/260,359 | Porta Sophia Files Third Party Submission

Patent application: preventing suicidal ideation in patients with life-threatening diseases

View Press Release

August 2, 2024 | 3rd Party Submission

Johns Hopkins University U.S. Patent Application 18/255,518 | Porta Sophia Files Third Party Submission

Patent application: iboga alkaloid compositions for treating neurological injuries

View Press Release

July 29, 2024 | 3rd Party Submission

Wesana Health Inc. U.S. Patent Application 18/254,705 | Porta Sophia Files Third Party Submission

Patent application: psilocybin compositions for the treatment of neurological conditions

View Press Release

July 26, 2024 | 3rd Party Submission

Wesana Health Inc. U.S. Patent Application 18/254,731 | Porta Sophia Files Third Party Submission

Patent application: psilocybin compositions for the treatment of migraine and related conditions

View Press Release

July 10, 2024 | 3rd Party Submission

Soneira Inc. PBC & Leland Stanford Junior University U.S. Patent Application 18/467,324 | Porta Sophia Files Third Party Submission

Patent application: compositions of iboga alkaloids and methods of treatment

View Press Release

July 9, 2024 | 3rd Party Submission

Xpira Pharmaceuticals U.S. Patent Application 18/447,553 | Porta Sophia Files Third Party Submission

Patent application: optimized psilocybin formulations

View Press Release

June 12, 2024 | Press Release

Porta Sophia Files Third-Party Preissuance Submission against DMT Vape U.S. Patent Application

Patent applications: vape pen to administer DMT and other psychedelics

View Press Release

May 22, 2024 | Press Release

Porta Sophia Files European Patent Opposition Against GH Research Ireland Limited’s Patent on 5-MeO-DMT for Treating Major Depression

European Patent No. 3 927 337: Use of 5-MeO-DMT for Treating Major Depressive Disorder

View Press Release

May 21, 2024 | 3rd Party Submission

CaaMTech, Inc. U.S. Patent Application 18/248,577 | Porta Sophia Files Third Party Submission

Patent application: tryptamine derivatives and their therapeutic uses

View Press Release

May 8, 2024 | 3rd Party Observation and Submission

New York University Applications PCT/US2023/060478 and 18/153,140 | Porta Sophia Files Third Party Observation and Submission

Patent applications: psilocybin for treatment of Alcohol Use Disorder

View Press Release

May 7, 2022 | 3rd Party Observation and Submission

Reset Pharmaceuticals, Inc. Applications PCT/US2023/022033 and 18/196,567 | Porta Sophia Files Third Party Observation and Submission

Patent applications: subcutaneous injection of psilocybin or psilocin for treatment

View Press Release

May 3, 2024 | 3rd Party Submission

Turtle Bear Holdings Applications 18/531,052 and 18/531,407 | Porta Sophia Files Third Party Observation and Submission

Patent applications: microdosing psilocybin

View Press Release

April 30, 2024 | 3rd Party Submission

GoodCap Pharmaceuticals U.S. Patent Application 18/248,626 | Porta Sophia Files Third Party Submission

Patent application: Compositions for reducing inflammation to improve or maintain mental or physical health

View Press Release

April 26, 2024 | 3rd Party Submission

Complex Matrix Solutions U.S. Patent Application 18/467,857 | Porta Sophia Files Third Party Submission

Patent Application: Oral encapsulations of psilocybin and psychedelic compounds

View Press Release

April 24, 2024 | 3rd Party Submission

Mydecine Innovations Group Inc. U.S. Patent Application 18/026,780 | Porta Sophia Files Third Party Submission

Patent Application: Psilocybin in combination with MDMA to modulate 5HT2A receptor activity

View Press Release

April 16, 2024 | 3rd Party Submission

Terran Biosciences U.S. Patent Application 18/339,172 | Porta Sophia Files Third Party Submission

Patent application: Tryptamine combinations with 5-HT2A antagonists

View Press Release

April 16, 2024 | 3rd Party Submission

Yale University U.S. Patent Application 18/308,357 | Porta Sophia Files Third Party Submission

Patent application: Treatment of depressive disorders with intravenous DMT compounds

View Press Release

April 1, 2024 | 3rd Party Submission

Universitatsspital Basel Patent Application 18/336,724 | Porta Sophia Files Third Party Submission

Patent application: Psychedelic dosing method for treating psychiatric conditions

View Press Release

March 21, 2024 | 3rd Party Submission

MiHKAL GmbH U.S. Patent Application 18/024,517 | Porta Sophia Files Third Party Submission

Patent Application: novel safrylamine derivatives having prodrug properties

View Press Release

March 20, 2024 | 3rd Party Submission

CaaMTech, Inc. Patent Application 18/350,103 | Porta Sophia Files Third Party Submission

Patent application: 5-MeO-DALT compounds

View Press Release

March 14, 2024 | 3rd Party Submission

Mind Medicine, Inc. U.S. Patent Application 18/196,992 | Porta Sophia Files Third Party Submission

Patent application: Desoxyscaline derivatives for changing neurotransmission

View Press Release

March 6, 2024 | 3rd Party Submission

Psilera Inc. U.S. Patent Application 18/229,286 | Porta Sophia Files Third Party Submission

Patent application: Intranasal administration of DMT and DMT fumarate

View Press Release

February 21, 2024 | 3rd Party Submission

Mind Medicine, Inc. U.S. Patent Application 17/734,098 | Porta Sophia Files Third Party Submission

Patent Application: titrating psychedelic dosing regimen to reduce hallucination side effects

View Press Release

February 19, 2024 | 3rd Party Submission

Louisiana State University U.S. Patent Application 17/984,011 | Porta Sophia Files Third Party Submission

Patent Application: Serotonin receptor agonists for ameliorating pathogenesis

View Press Release

February 15, 2024 | 3rd Party Submission

ATAI Life Sciences AG U.S. Patent Application 18/116,195 | Porta Sophia Files Third Party Submission

Patent Application: R-MDMA HCl polymorph synthesis and characterization

View Press Release

February 14, 2024 | Press Release

Porta Sophia Publishes in Harvard Law School’s Bill of Health

Case study of the psychedelic biotech company MindMed, Inc. and patent applications that infringe on the public domain

View Press Release

January 12, 2024 | 3rd Party Submission

Mind Medicine, Inc. U.S. Patent Application 18/186,764 | Porta Sophia Files Third Party Submission

Patent Application: R-MDMA enantiomer to treat broad range of disorders

View Press Release

January 10, 2024 | 3rd Party Submission

Diamond Therapeutics Inc. U.S. Patent Application 18/102,268 | Porta Sophia Files Third Party Submission

Patent Application: methods of treatment for neurological and neuropsychiatric conditions with LSD

View Press Release

January 10, 2024 | 3rd Party Submission

PSYRX LTD. U.S. Patent Application 18/003,561 | Porta Sophia Files Third Party Submission

Patent Application: Combination of ibogaine and antidepressant to treat psychiatric disorders

View Press Release

January 8, 2023 | 3rd Party Submission

Lobe Sciences LTD. U.S. Patent Application 18/009,161 | Porta Sophia Files Third Party Submission

Patent Application: Combination of MDMA and N-acetylcysteine to Treat PTSD and mTBI

View Press Release

November 20, 2023 | 3rd Party Submission

University of Zürich U.S. Patent Application 18/012,122 | Porta Sophia Files Third Party Submission

Patent Application: composition comprising DMT and harmine

View Press Release

October 30, 2023 | 3rd Party Submission

The Royal Institution for the Advancement of Learning and McGill University U.S. Patent Application 18/102,296 | Porta Sophia Files Third Party Submission

Patent Application: methods of treatment for neurological and neuropsychiatric conditions with LSD

View Press Release

October 30, 2023 | 3rd Party Observation and Submission

Mind Medicine, Inc. Applications PCT/US2022/033308 and 17/839,374, Porta Sophia Files Third Party Observation and Submission

Patent application: computer application for monitoring a psychedelic therapeutic session

View Press Release

October 12, 2023 | 3rd Party Submission

The Beckley Foundation U.S. Patent Application 17/905,549 | Porta Sophia Files Third Party Submission

Patent Application: LSD for Treatment of Pain

View Press Release

October 9, 2023 | 3rd Party Submission

Emergex USA Corporation U.S. Patent Application 17/997,094 | Porta Sophia Files Third Party Submission

Patent application: transdermal delivery of psychedelics via microprojections

View Press Release

September 20, 2023 | 3rd Party Submission

Turtle Bear Holdings, LLC U.S. Patent Application 18/114,381 | Porta Sophia Files Third Party Submission

Patent application: treatment of depression with baeocystin, norbaeocystin, and psilocybin

View Press Release

September 14, 2023 | 3rd Party Submission

Terran Biosciences Inc. U.S. Patent Application 17/989,673 | Porta Sophia Files Third Party Submission

Patent application: solid formulations of empathogenic compounds

View Press Release

September 6, 2023 | 3rd Party Submission

Mind Medicine, Inc U.S. Patent Application 18/194,761 | Porta Sophia Files Third Party Submission

Patent application: oral lyophilized tablet immediate release LSD formulation

View Press Release

September 5, 2023 | 3rd Party Submission

Eleusis Health Solutions U.S. Patent Application 17/910,452 | Porta Sophia Files Third Party Submission

Patent application: enhancements to psychedelic therapy safety

View Press Release

September 1, 2023 | Application Abandoned

Application Abandoned for Pike Therapeutics Inc. U.S. Patent Application 17/231,553 Describing Transdermal Psychedelic Microdosing

Patent Application: Transdermal microdosing of psychedelics

View Press Release

August 18, 2023 | 3rd Party Observation

Beckley Psytech Limited International Patent Application PCT/GB2022/053123, Porta Sophia Files Third Party Observation

Patent Application: Method of Producing Polymorph A’ of Psilocybin

View Press Release

August 14, 2023 | 3rd Party Observation

Mind Medicine, Inc. International Patent Application PCT/US2022/040636, Porta Sophia Files Third Party Observation

Patent Application: oral lyophilized tablet immediate release LSD formulation

View Press Release

August 3, 2023 | 3rd Party Submission

Turtle Bear Holdings, LLC U.S. Patent Application 18/115,966 | Porta Sophia Files Third Party Submission

Patent application: norpsilocin and niacin to treat neurological disorders

View Press Release

July 31, 2023 | 3rd Party Submission

Lobe Sciences LTD U.S. Patent Application 17/916,855 | Porta Sophia Files Third Party Submission

Patent application: N-acetyl-cystine and psilocybin for traumatic brain injury and/or PTSD

View Press Release

July 8, 2023 | 3rd Party Submission

Orthogonal Thinker, Inc. U.S. Patent Application 17/912,821 | Porta Sophia Files Third Party Submission

Patent application: psilocybin compositions generated via tincture extraction

View Press Release

July 6, 2023 | 3rd Party Submission

The Regents of the University of California U.S. Patent Application 17/915,884 | Porta Sophia Files Third Party Submission

Patent application: monitoring neural and physiological status while using a psychedelic

View Press Release

July 5, 2023 | 3rd Party Observation

Eleusis Therapeutics Inc. International Patent Application PCT/US2022/043580, Porta Sophia Files Third Party Observation

Patent Application: LSD formulated in chewing gum

View Press Release

July 3, 2023 | Press Release

Porta Sophia Achieves Landmark Milestone: 50 Third-Party Interventions Filed

Porta Sophia Milestone: 50 Third-Party Interventions Filed

View Press Release

July 3, 2023 | 3rd Party Observation

Mind Medicine Inc. Patent Application PCT/US2022/026921, Porta Sophia Files Third Party Observation

Patent Application: method of treating pain using psychedelics

View Press Release

June 22, 2023 | Application Abandoned

Application Abandoned for Pharma America Holding U.S. Patent Application 17/525,248 Describing MDMA combined with Viagra® for enhanced sexual desire and ability

Patent Application: MDMA combined with Viagra® for enhanced sexual desire and ability

View Press Release

June 21, 2023 | 3rd Party Observation and Submission

University Hospital of Basel Applications PCT/IB2022/054049 and 17/734,601, Porta Sophia Files Third Party Observation and Submission

Patent application: LSD and psilocybin dosing system

View Press Release

June 21, 2023 | 3rd Party Observation and Submission

Pike Therapeutics Inc. Applications PCT/IB2022/057210 and 17/879,846, Porta Sophia Files Third Party Observation and Submission

Patent application: transdermal administration of sub-hallucinogenic dosages of psychedelics

View Press Release

June 15, 2023 | Claims Rejection

All Claims Rejected for ATAI Life Sciences U.S. Patent Application 17/941,648 Describing Ibogaine Co-Administration with a Metabolism Inhibitor for Safer Therapies

Patent Application: Ibogaine Co-Administration with a Metabolism Inhibitor for Safer Therapies

View Press Release

June 14, 2023 | 3rd Party Submission

ECP Pharma Application 18/045,843 | Porta Sophia Files Third Party Submission

Patent application: cannabidiol and psilocybin combinations to treat traumatic brain injuries

View Press Release

June 14,2023 | 3rd Party Submission

GH Research Ireland Limited Application 17/801,389 | Porta Sophia Files Third Party Submission

Patent application: 5-MeO-DMT aerosol for inhalation

View Press Release

June 12, 2022 | 3rd Party Submission

Psilothera Inc. Application 17/459,998 | Porta Sophia Files Third Party Submission

Patent application: method of providing psychedelic-assisted therapy via telehealth

View Press Release

June 09, 2023 | 3rd Party Observation and Submission

Mind Medicine Inc. Applications PCT/US2022/032601 and 17/835,501, Porta Sophia Files Third Party Submission and Observation

Patent application: 18-methoxycoronaridine to treat obesity 

View Press Release

June 08, 2023 | 3rd Party Submission

Mind Medicine, Inc Application 17/877,521 | Porta Sophia Files Third Party Submission

Patent application: psychedelic treatment of pain

View Press Release

June 07, 2023 | 3rd Party Submission

Mind Medicine, Inc Application 17/732,878, Porta Sophia Files Third Party Submission

Patent application: psychedelic treatment of pain

View Press Release

June 07, 2023 | 3rd Party Submission

Mind Medicine Inc. Applications 17/890,198 and PCT/US2022/040653, Porta Sophia Files Third Party Submission and Observation

Patent application: Immediate release D-lysergic acid diethylamide (LSD)

View Press Release

June 02, 2023 | 3rd Party Observation and Submission

ATAI Life Sciences Applications 17/957,851 and PCT/US2022/045336, Porta Sophia Files Third Party Submission and Observation

Patent application: 5-MeO-DMT and bufotenine to treat headache disorders

View Press Release

May 26, 2023 | 3rd Party Observation and Submission

ATAI Life Sciences Applications 17/941,648 and PCT/US2022/043102, Porta Sophia Files Third Party Submission and Observation

Patent application: ibogaine co-administration with a metabolism inhibitor for safer therapies

View Press Release

May 23, 2023 | Claims Rejection

All Claims Rejected for CaaMTech Inc. U.S. Patent Application 17/095,430 Describing Combinations of Serotonergic Drugs

Patent Application: combinations of serotonergic drugs

View Press Release

May 11, 2023 | 3rd Party Submission

SW Holdings, Inc Application 17/624,377 | Porta Sophia Files Third Party Submission

Patent application: metered dosing formulations for psychedelics

View Press Release

May 4, 2023 | 3rd Party Submission

Neonmind Biosciences Inc. Application 17/782,582, Porta Sophia Files Third Party Submission

Patent application: psilocybin to treat obesity, eating disorders, and their complications

View Press Release

April 26, 2023 | 3rd Party Observation and Submission

Panagiotakopoulos et al Applications 17/948,180 and PCT/US2022/044039, Porta Sophia Files Third Party Submission and Observation

Patent application: composition of psilocybin, psilocin, baeocystin and norpsilocin

View Press Release

April 20, 2023 | Claims Rejection

All Claims Rejected for Diamond Therapeutics Inc. US Patent Application 17/427,037 Describing 5HT Receptor Agonists at Sub-Hallucinogenic Levels as Neurological Treatment

Patent Application: 5HT Receptor Agonists at Sub-Hallucinogenic Levels as Neurological Treatment

View Press Release

April 18, 2023 | 3rd Party Observation

Universitätsspital Basel (University Hospital of Basel) Patent Application PCT/IB2022/052189, Porta Sophia Files Third Party Observation

Patent Application: Co-Treatment of Antidepressant and Psychedelic

View Press Release

April 12, 2023 | 3rd Party Submission

CaaMTech U.S. Patent Application 17/620,855, Porta Sophia Files Third Party Submission

Patent Application: Purified Ibogaine and Ibogaine Derivatives for the Treatment of Addiction and Depression

View Press Release

April 10, 2023 | 3rd Party Submission

Mind Medicine, Inc. U.S. Patent Application 17/833,829, Porta Sophia Files Third Party Submission

Patent Application: Psychedelics Taken with 5-HT2A Antagonists to Control Psychedelic Trip Duration

View Press Release

March 29, 2023 | 3rd Party Submission

Universitätsspital Basel (University Hospital of Basel) Application 17/692,105, Porta Sophia Files Third Party Submission

Patent Application: Co-Treatment of Antidepressant and Psychedelic

View Press Release

March 16, 2023 | Claims Rejection

All Claims Rejected for Universitätsspital Basel US Patent Application Describing Mescaline and Analogs to Treat Medical Conditions

USPTO directly cites prior art included in Porta Sophia's third-party preissuance submission in establishing application's lack of novelty and non-obviousness

View Press Release

March 10, 2023 | Claims Rejection

All Claims Rejected for University of Maryland, Baltimore US Patent Application Describing Psilocybin and Ketanserin or Ritanserin to Treat Depression

USPTO directly cites prior art included in Porta Sophia's third-party preissuance submission in establishing application's lack of novelty and non-obviousness

View Press Release

March 10, 2023 | 3rd Party Submission

Journey Colab Corp International Patent Application, Porta Sophia Files Third Party Submission

Patent Application: Mescaline for Treatment of Substance Use Disorders

View Press Release

March 6, 2023 | 3rd Party Submission

Porta Sophia Files Third-Party Preissuance Submission for Turtle Bear Holdings, LLC U.S. Patent Application

Patent Application: Psychedelics Combined With Lion's Mane Mushrooms and Monoamine Oxidase Inhibitors To Modulate Inflammation Caused by Infection

View Press Release

February 23, 2023 | Claims Rejection

All Claims Rejected for Universitätsspital Basel US Patent Application Describing MDMA to Enhance Emotional Effects of Psychedelics

USPTO directly cites prior art included in Porta Sophia's third-party preissuance submission in establishing application's lack of novelty and non-obviousness

View Press Release

February 23, 2023 | 3rd Party Observation

Mind Medicine, Inc International Patent Application, Porta Sophia Files Third Party Observation

Psychedelic prior art library presents four documents challenging patentability of 23 application claims

View Press Release

February 17, 2023 | 3rd Party Submission

University of Maryland, Baltimore U.S. Patent Application, Porta Sophia Files Third Party Submission

Psychedelic prior art library presents three documents challenging patentability of all claims

View Press Release

January 30, 2023 | Press Release

Porta Sophia Responds to USPTO Request for Comments on Initiatives to Ensure the Robustness and Reliability of Patent Rights

View Press Release

January 23, 2023 | 3rd Party Observation

Universitätsspital Basel Patent Application, Porta Sophia Files Third Party Observation

Psychedelic prior art library presents 14 documents challenging patentability of all application claims

View Press Release

January 20, 2023 | 3rd Party Submission

University of Basel Application, Porta Sophia Files Third-Party Preissuance Submission

Psychedelic prior art library presents 13 documents challenging patentability of all application claims

View Press Release

January 12, 2023 | 3rd Party Submission

Arbormentis LLC U.S. Patent Application, Porta Sophia Files Third-Party Preissuance Submission

Psychedelic prior art library presents 26 documents challenging patentability of all claims

View Press Release

January 6, 2023 | 3rd Party Submission

Mind Medicine Inc. U.S. Patent Application, Porta Sophia Files Third-Party Preissuance Submission

Psychedelic prior art library presents seven documents challenging patentability of all claims

View Press Release

December 15, 2022 | 3rd Party Submission

Turtle Bear Holdings U.S. Patent Application, Porta Sophia Files Third-Party Preissuance Submission

Psychedelic prior art library presents five documents challenging patentability of all claims

View Press Release

December 14, 2022 | Press Release

All Claims of Pharma America Holding US Patent Application Describing MDMA in Combination with Viagra® Rejected

USPTO directly cites prior art included in Porta Sophia's third-party preissuance submission in establishing application's lack of novelty

View Press Release

November 23, 2022 | 3rd Party Submission

Shawn Joseph U.S. Patent Application, Porta Sophia Files Third-Party Preissuance Submission

Psychedelic prior art library presents 10 documents challenging patentability of all application claims

View Press Release

November 23, 2022 | 3rd Party Observation

Mynd Life Sciences International Patent Application, Porta Sophia Files Third-Party Observation

Psychedelic prior art library presents 2 documents challenging patentability of all application claims

View Press Release

November 22, 2022 | 3rd Party Observation

Compass Pathfinder Limited Patent Application, Porta Sophia Files Third-Party Observation

Psychedelic prior art library presents 4 documents challenging patentability of 38 of 52 claims

View Press Release

November 1, 2022 | 3rd Party Observation

GoodCap Pharmaceuticals Patent Application, Porta Sophia Files Third-Party Observation

Psychedelic prior art library presents 16 documents challenging patentability of all application claims

View Press Release

October 5, 2022 | Press Release

Yale Patent Application Claims Rejected as Unpatentable Based on References Submitted to the USPTO by Porta Sophia

View Press Release

August 25, 2022 | Press Release

COMPASS Pathways Amends Claims of US Patent Application Describing Psilocybin for the Treatment of Depression

Psychedelic drug company submits revised, narrower set of claims five months after Porta Sophia's third-party preissuance submission challenged patentability

View Press Release

August 23, 2022 | 3rd Party Observation

Wesana Health International Patent Application, Porta Sophia Files Third-Party Observation

Psychedelic prior art library presents 5 documents challenging patentability of 105 claims

View Press Release

July 22, 2022 | 3rd Party Submission

CaaMTech U.S. Patent Application, Porta Sophia Files Third-Party Preissuance Submission

sychedelic prior art library presents 9 documents challenging patentability of all claims

View Press Release

July 22, 2022 | 3rd Party Submission

Pharma America Holding Inc. U.S. Patent Application, Porta Sophia Files Third-Party Preissuance Submission

Psychedelic prior art library presents 9 documents challenging patentability of all claims

View Press Release

July 22, 2022 | 3rd Party Submission

Diamond Therapeutics Inc. U.S. Patent Application, Porta Sophia Files Third-Party Preissuance Submission

Psychedelic prior art library presents 8 documents challenging patentability of all claims

View Press Release

June 16, 2022 | 3rd Party Submission

GH Research Ireland Limited U.S. Patent Application, Porta Sophia Files Third-Party Preissuance Submission

Psychedelic prior art library presents 23 documents challenging patentability of all claims

View Press Release

June 7, 2022 | 3rd Party Submission

Turtle Bear Holdings LLC U.S. Patent Application, Porta Sophia Files Third-Party Preissuance Submission

Psychedelic prior art library presents 8 documents challenging patentability of all claims

View Press Release

April 14, 2022 | 3rd Party Submission

University of Basel Patent Application, Porta Sophia Files Third-Party Preissuance Submission

Psychedelic prior art library presents 21 documents challenging patentability of all claims of University of Basel application

View Press Release

April 5, 2022 | 3rd Party Submission

Pike Therapeutics Inc. Patent Application, Porta Sophia Files Third-Party Preissuance Submission

Psychedelic prior art library presents 23 documents challenging patentability of all claims of Pike Therapeutics Inc. application

View Press Release

March 9, 2022 | 3rd Party Submission

COMPASS Pathways Patent Application, Porta Sophia Files Third-Party Preissuance Submission

Psychedelic prior art library presents 39 documents challenging patentability of all claims of COMPASS Pathways application

View Press Release

February 23, 2022 | 3rd Party Submission

Porta Sophia Files Third-Party Preissuance Submission For Patent Application Filed By Yale University and the US Department of Veterans Affairs

Psychedelic prior art library presents five documents challenging patentability of all claims of the application filed by co-applicants Yale University and The United States of America as represented by the Department of Veterans Affairs

View Press Release

December 16, 2021 | 3rd Party Submission

CaaMTech Inc. Cancels All Claims of US Patent Application Describing Serotonergic Drug Combinations

Psychedelic drug company submits revised, narrower set of claims within a month of Porta Sophia’s third-party preissuance submission challenging patentability

View Press Release

November 19, 2021 | 3rd Party Submission

Porta Sophia Files Third-Party Preissuance Submission For CaaMTech Inc. Patent Application

Psychedelic prior art library presents 18 documents challenging patentability of all claims of CaaMTech Inc. application

View Press Release
Learn about the status and impact of Porta Sophia's third party submissions and observations.

View Our Summary Chart